Table 1. Tangeretin pre-treatment improved liver function and inhibited cisplatin-induced aberrations in lipids profile.
| ALT (U/l) | AST (U/l) | Triglyceride (mg/dl) | Total Cholesterol (mg/dl) | |
|---|---|---|---|---|
| Normal | 24.5 ± 1.7 | 112.3 ± 13.6 | 53.3 ± 3.5 | 72.3 ± 4.9 |
| Silymarin (100 mg/kg) | 25.5 ± 3.1 | 112.5 ± 12.5 | 57.5 ± 5.2 | 69.5 ± 8.2 |
| Tangeretin (100 mg/kg) | 27.5 ± 2.4 | 114.3 ± 17.2 | 62.2 ± 8.4 | 71.6 ± 4.2 |
| Cisplatin | 77.3 ± 7.0* | 290.0 ± 38.3* | 175.2 ± 19.7* | 138.0 ± 12.8* |
| Cisplatin + Silymarin (100 mg/kg) | 38.8 ± 4.6# | 136.2 ± 12.7# | 111.0 ± 12.5# | 89.6 ± 10.5# |
| Cisplatin + Tangeretin (50 mg/kg) | 68.0 ± 5.1 | 252.8 ± 36.1 | 159.7 ± 20.2 | 122.4 ± 5.4 |
| Cisplatin + Tangeretin (100 mg/kg) | 35.8 ± 4.2# | 132.2 ± 12.3# | 84.8 ± 13.1# | 82.5 ± 6.3# |
Values are mean± SD of the mean (n = 4–5 independent values). Statistical analysis was carried out by using one way analysis of variance (ANOVA) followed by Tukey-Kramer multiple comparisons test
* Significantly different from normal control at p < 0.05.
# Significantly different from cisplatin-treated (7.5 mg/kg) animals at p < 0.05.